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Summary Statement 
Neural tube defects in a folic acid-responsive, folate-sensitive mouse model are associated with 
a localized proliferation defect in the neuroepithelium. Supplemental folic acid stimulates 
progression through S-phase of the cell cycle and corrects this abnormality. 
 
 
Abstract 
Neural tube defects (NTDs), including spina bifida and anencephaly, are among the most 
common birth defects worldwide but the underlying genetic and cellular causes are not well 
understood. Some NTDs are preventable by supplemental folic acid. However, the protective 
mechanism is unclear despite widespread use of folic acid supplements and implementation of 
food fortification in many countries. Pax3 mutant (splotch; Sp2H) mice provide a model in which 
NTDs are preventable by folic acid and exacerbated by maternal folate deficiency. Here, we 
found that cell proliferation was diminished in the dorsal neuroepithelium of mutant embryos, 
corresponding to the region of abolished Pax3 function. This was accompanied by premature 
neuronal differentiation in the prospective midbrain. Contrary to previous reports, we did not 
find evidence that increased apoptosis could underlie failed neural tube closure in Pax3 mutant 
embryos, nor did inhibition of apoptosis prevent NTDs. These findings suggest that Pax3 
functions to maintain the neuroepithelium in a proliferative, undifferentiated state allowing 
neurulation to proceed. NTDs in Pax3 mutants were not associated with abnormal abundance 
of specific folates, nor prevented by formate, a one-carbon donor to folate metabolism. 
Supplemental folic acid restored proliferation in the cranial neuroepithelium. This effect was 
mediated by enhanced progression of the cell cycle from S- to G2-phase, specifically in the 
Pax3-mutant dorsal neuroepithelium. We propose that the cell cycle-promoting effect of folic 
acid compensates for loss of Pax3 and thereby prevents cranial NTDs.  
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Introduction 
Neural tube defects (NTDs) such as anencephaly and spina bifida are among the most common 
birth defects worldwide, affecting more than 250,000 pregnancies every year (Copp et al., 
2013; Zaganjor et al., 2016). Maternal use of supplemental folic acid (FA) prevents a proportion 
of NTDs (Berry et al., 1999; Czeizel and Dudás, 1992; MRC Vitamin Study Research Group, 1991) 
and FA food fortification programmes, which now exist in many countries, have generally been 
associated with a reduction in NTD prevalence, compared with historical pre-fortification 
frequencies (Berry et al., 2010; Castillo-Lancellotti et al., 2013). A key aim for public health 
efforts is now to ensure that women who may become pregnant achieve recommended daily 
intakes of FA, in order to lower NTD rates (Martinez et al., 2018). However, there is still a gap in 
our knowledge concerning the mechanism by which FA prevents NTDs in the developing 
embryo. FA is the synthetic form of folate, a term which refers to a group of molecules, based 
on a tetrahydrofolate (THF) backbone, that carry one-carbon units in folate one-carbon 
metabolism. FA is converted via dihydrofolate to THF, with subsequent addition of one-carbon 
groups derived principally from serine, glycine and formate (Tibbetts and Appling, 2010; Leung 
et al., 2017). 
 
NTDs result from incomplete closure of the neural tube during embryonic development 
(Greene and Copp, 2014; Nikolopoulou et al., 2017). Among mouse genetic models, 
exencephaly and/or spina bifida arise in splotch mice, carrying mutations of the paired-box-
domain-containing transcription factor Pax3 (Epstein et al., 1991; Greene et al., 2009). Notably, 
Pax3 mutants (Pax3Sp2H, Pax3Sp)  are among the very few models in which NTDs have been 
found to be both preventable by supplemental folic acid and exacerbated by maternal folate 
deficiency, imposed by diet and administration of antibiotic to remove folate-synthesizing gut 
bacteria (Burren et al., 2008; Fleming and Copp, 1998; Wlodarczyk et al., 2006). Hence, NTDs in 
this model are both folic acid-responsive and folate-sensitive. In addition to mutation of the 
Pax3 gene itself, suppression of Pax3 expression in mouse embryos is also proposed to 
contribute to NTDs induced by environmental factors, such as maternal diabetes (Fine et al., 
1999; Machado et al., 2001) and polycyclic aromatic hydrocarbons (Lin et al., 2019). 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
Mutations of the human PAX3 coding sequence have been identified in some individuals with 
NTDs (Hart and Miriyala, 2017) and may contribute to a minority of NTDs. Altered methylation 
of PAX3 has also been identified in NTD cases, suggesting that altered expression could 
potentially play a contributory role (Lin et al., 2019).  
 
Understanding the mechanisms by which Pax3 loss of function prevents neural tube closure will 
not only give insight into possible causes of NTDs but may also provide an opportunity to better 
understand the means by which FA prevents NTDs. It has been proposed that Pax3-related 
NTDs (specifically the Pax3Sp allele) result from excess apoptosis: NTDs were prevented by 
genetic or pharmacological suppression of p53 function (Pani et al., 2002), leading to the 
hypothesis that Pax3 functions to suppress p53-dependent apoptosis in the neuroepithelium. A 
p53-dependent excess of apoptosis has also recently been proposed to underlie NTDs 
associated with zinc deficiency (Li et al., 2018). Both excess and insufficient apoptosis have 
been associated with exencephaly in other mouse mutants, although in most cases a causal 
relationship has not been definitively proven (Greene and Copp, 2014; Nikolopoulou et al., 
2017). 
 
Other studies of apoptosis in splotch (Pax3Sp) embryos have produced differing findings.  For 
example, increased TUNEL staining was reported in the neural tube at E10.5 (Pani et al., 2002), 
whereas no change in the number of pyknotic nuclei in the spinal neuroepithelium was 
detected at E9.5 (Kapron-Bras and Trasler, 1988). Moreover, whilst aberrant levels of apoptosis 
have been demonstrated in Pax3Sp/Sp and Pax3Sp2H/Sp2H mutants in the dermomyotome of the 
developing somites, increased apoptosis was not observed in the neural tube at E9.5 or later 
stages (Borycki et al., 1999; Mansouri et al., 2001). In the current study we sought to address 
the question of the possible contributory role of apoptosis to NTDs in the Pax3Sp2H/Sp2H model 
and to investigate other potential causative cellular abnormalities. Having identified a tissue-
specific defect in cellular proliferation, we went on to ask whether this abnormality was 
corrected by folic acid supplementation in association with prevention of NTDs. 
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Results  
NTDs in Pax3 (Sp2H) mutant embryos do not result from excess apoptosis 
NTDs in splotch embryos result from a cell autonomous defect in the neuroepithelium 
(Goulding et al., 1991; Li et al., 1999). Therefore, if excess apoptosis is the cause of cranial NTDs 
in Pax3 mutants, this should be detectable prior to and/or during closure of the cranial 
neuroepithelium which has not previously been examined. 
 
The initiation of neural tube closure, at the hindbrain-cervical boundary (Closure 1; 5-6 somites; 
E8.5) and in the posterior forebrain (Closure 2; 9-10 somites; E9.0) occur similarly in 
Pax3Sp2H/Sp2H embryos as in wild-type littermates. However, progression of ‘zippering’ forwards 
from Closure 1 and backwards from Closure 2 fails in those mutants that develop 
midbrain/hindbrain exencephaly (Fleming and Copp, 2000). In the current study, exencephaly, 
characterized by persistently open cranial neural folds, arose in 65% of Pax3Sp2H/Sp2H mutants (n 
= 46), whereas all Pax3+/+ embryos (n = 54) completed closure by the 16 somite stage at E9.5 
(p<0.001; Chi-square). 
 
In Pax3+/+ and Pax3Sp2H/Sp2H embryos, TUNEL-positive cells were detected in the rostral 
forebrain, the midline of the closed forebrain neural tube and in the hindbrain neural folds (Fig. 
1A-F), corresponding to known sites of apoptosis in wild-type embryos (Massa et al., 2009; 
Mirkes et al., 2001). However, we did not observe an increase in the number or location of 
TUNEL-positive cells in the neural folds of Pax3Sp2H/Sp2H embryos at any stage of closure in either 
the cranial or spinal region (Fig. 1; Fig. S1). Consistent with the results of TUNEL staining, the 
number of cleaved caspase-3 positive, apoptotic cells in the cranial neural folds did not differ 
between genotypes (Fig. 1G). 
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Although not supported by our TUNEL and cleaved caspase-3 analysis, we reasoned that if 
apoptosis is indeed causally related to splotch NTDs then direct inhibition of apoptosis would 
potentially rescue these defects. Therefore, as a complementary approach, embryos were 
cultured through the period encompassing cranial neurulation (40 hours from E8.5) in the 
presence of the pan-caspase inhibitor Z-VAD-FMK, which we previously showed to effectively 
suppress apoptosis in neurulation-stage embryos (Massa et al., 2009)(Fig. 2). Contrary to 
predictions, inhibiting apoptosis caused a dose-dependent increase in exencephaly incidence 
among Pax3Sp2H/Sp2H embryos. These defects were also observed among some heterozygotes, 
which are unaffected in the absence of Z-VAD-FMK (Fig. 2E). In addition, the posterior 
neuropore (PNP) length of Sp2H/+ embryos treated with 200 µM Z-VAD-FMK was greater than 
among vehicle-treated controls, suggesting suppression of spinal neural tube closure (Table S1). 
Wild-type embryos were unaffected by the inhibitor. Moreover, there was no apparent effect 
of Z-VAD-FMK on viability, growth or developmental progression compared to vehicle-treated 
controls, showing that increased exencephaly frequency does not result from generalised non-
specific teratogenicity (Table S1). Hence, inhibition of apoptosis does not prevent NTDs and 
may even interact with genetic mutation of Pax3 to increase the susceptibility to NTDs in 
embryos carrying the Sp2H allele. Overall, our data do not support the hypothesis that NTDs 
result from increased apoptosis in Pax3 mutant embryos. 
 
Pax3 mutation results in premature neuronal differentiation in the cranial neuroepithelium 
prior to failure of closure 
We next asked whether the frequency of cranial NTDs in Pax3Sp2H/Sp2H embryos can be lowered 
by maternal treatment with pifithrin-, as described for embryos homozygous for the Sp allele 
of Pax3 (Pani et al., 2002). We found a lower frequency of cranial NTDs (Fig. 3A-B) among 
Pax3Sp2H/Sp2H offspring of pifithrin-α treated mice compared with untreated control litters (Fig. 
3A; Table S2). 
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Pifithrin- was originally identified in a screen for inhibitors of p53 (Murphy et al., 2004), 
suggesting this as a mode of action in Pax3 mutants. Surprisingly however, among litters 
generated by intercross of Pax3Sp2H/+; Trp53+/- mice we found no effect of p53 genotype on the 
susceptibility to NTDs in Pax3Sp2H/Sp2H embryos (Table 1). Cranial NTDs occurred among some 
Trp53-/- embryos that were wild-type, as predicted from previous reports (Sah et al., 1995), 
demonstrating effectiveness of the Trp53 mutant allele. Moreover, Trp53 mutation caused an 
increased rate of cranial NTDs in Pax3Sp2H/+ heterozygotes (Table 1). Lack of replication of the 
reported NTD prevention in Pax3Sp/Sp; Trp53-/- embryos (Pani et al., 2002) could potentially 
reflect an allele-specific difference between Sp, which primarily causes spinal NTDs, and Sp2H 
which causes both cranial NTDs (approximately 60% of homozygotes) and almost fully 
penetrant spina bifida (Burren et al., 2008; Greene et al., 2009).  
 
Possible cellular responses to p53 activity include not only apoptosis but also cell cycle arrest, 
senescence and differentiation (Vousden and Lane, 2007). Therefore, in view of the 
inconsistent findings with apoptosis inhibition, pifithrin- usage and genetic knockout of p53, 
we asked whether cellular differentiation and/or cell cycle progression may be dysregulated in 
the neuroepithelium of Pax3 mutant embryos. 
 
In wild-type embryos, the onset of neuronal differentiation correlated closely with the timing of 
cranial neural tube closure at E9.5 (Fig. 3). Few cells were positive for the early neuronal 
marker, β-tubulin type III (TuJ1), in the midbrain neuroepithelium at the 13-15 somite stages, 
prior to closure (Fig. 3G, K). Neuronal differentiation then increased, concomitantly with 
completion of cranial neural tube closure, which is achieved in wild-type embryos by the 16 
somite stage (Fig. 3K). In contrast, Pax3Sp2H/Sp2H embryos showed a pronounced shift in the 
timing of neuronal differentiation in the midbrain, compared with wild-type embryos, with 83% 
and 210% increases in the number of Tuj1 positive cells at the 14 and 15 somite stages, 
respectively (Fig. 3H, I, K). These supernumerary neuronal cells arose in the dorsal region of 
neuroepithelium corresponding to the Pax3 expression domain (Fig. 3C-D; Fig. S2), suggesting 
that differentiation occurred as a result of loss of Pax3 function. Hence, excess neuronal cells 
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were present in the midbrain neuroepithelium prior to failure of closure and at a stage when 
they are scarce in wild-type controls. Forebrain closure occurs successfully in Pax3 mutant 
embryos, a region in which Pax3 expression is weaker than at other axial levels of the neural 
tube (Fig. 3B-C). This region exhibited low numbers of Tuj1-positive cells at E9.5 with no 
difference between genotypes (Fig. 3E, F, L). 
 
Among pifithrin-α treated embryos, concomitant with prevention of exencephaly in 
Pax3Sp2H/Sp2H embryos, there was a significant reduction in the number of TuJ1-positive cells in 
the midbrain neuroepithelium (Fig. 3J-K). Thus, our findings suggest that normalization of 
neural tube closure in Pax3 mutant embryos following pifithrin- treatment, may be mediated, 
not via prevention of p53-dependent apoptosis, but through suppression of premature 
neuronal differentiation. 
 
Impaired cell cycle progression in Pax3-deficient neuroepithelium 
We investigated the possibility that premature neuronal differentiation could be associated 
with altered proliferation in the neuroepithelium of Pax3Sp2H/Sp2H embryos. At neurulation 
stages, Pax3Sp2H/Sp2H embryos had comparable number of somites and crown-rump length to 
wild-type littermates, showing that there is no overall growth or developmental retardation 
(Table S3). However, we observed a significant deficit in the proportion of phospho-histone H3 
(PHH3) labelled cells at late G2/M phase in the dorsal neural plate of Pax3Sp2H/Sp2H embryos (Fig. 
3M). Hence, a dorsal-high, ventral-low proliferation differential was observed in the midbrain 
neuroepithelium of wild-type embryos at E9.5, consistent with findings in the spinal neural tube 
(Kim et al., 2007; McShane et al., 2015; Megason and McMahon, 2002), whereas this 
proliferation differential was absent in Pax3Sp2H/Sp2H mutants (Fig. 3M). 
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Failure of spinal neurulation is associated with diminished proliferation but not premature 
neuronal differentiation 
The observation of premature neuronal differentiation and diminished proliferation in the 
dorsal cranial neuroepithelium at the stage of closure suggest potential causative mechanisms 
for cranial NTDs. We therefore asked whether comparable phenotypes were present in the 
spinal neural folds. Spina bifida occurs in almost all Pax3Sp2H/Sp2H embryos, and results from 
failure of PNP closure at E10.5. Measurements of PNP length showed that spinal neural tube 
closure was delayed from soon after initiation of closure with an enlarged PNP evident at E9.0 
(12-13 somite stage) and becoming particularly prominent from E9.5 (14-16 somite stage) 
onwards (Fig. 4A; Fig. S2E). The PNP did not dramatically increase in size as development 
progresses, unlike in mutants such as Grhl3-/- (De Castro et al., 2018), indicating that closure 
progresses in Pax3 mutants. However, this is at a diminished speed such that closure ultimately 
fails to be completed in the low spine. 
 
Arguing against a primary effect in which the presence of neuronal cells causes spina bifida, 
abnormal neuronal differentiation was not apparent in the spinal neuroepithelium of Pax3 
mutants at E9.5. Neuronal differentiation proceeds in a rostro-caudal temporal wave and, in 
embryos of all genotypes, Tuj1 staining (whole mount and on sections) was apparent only in the 
closed neural tube rostral to the site of PNP zippering. Neurons were never observed in the 
open PNP region of Pax3+/+ (n = 6), Pax3Sp2H/Sp2H (n = 7) or Pax3Sp2H/+ (n = 7) embryos (Fig. 4B, C; 
Fig. S3). Moreover, the caudal axial level at which Tuj1-positive cells was detected in the closed 
neural tube did not differ between genotypes (Fig. S3).  
 
As observed in the cranial region (Fig. 3M), the dorsal neuroepithelium of Pax3Sp2H/Sp2H embryos 
exhibited an apparent proliferation defect. Hence, at the 14-15 somite stage (E9.5), soon after 
delay of PNP closure become apparent, immunostaining for PHH3 at the rostral level of the PNP 
revealed a significant decrease in the proportion of cells at late G2/M-phase in the dorsal 
neural plate (Fig. 4D-E), corresponding to the region of Pax3 loss of function (Fig. S2B). This 
proliferation deficit abolishes the dorsal-ventral proliferation difference that is present in wild-
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type embryos at this stage (Fig. 4E; Fig. S4A-B) and led to a significant reduction in the number 
of cells in the neuroepithelium (Fig. 4F), including in both dorsal and ventral sub-regions (Fig. 
S4C-E). In parallel with this finding, the cross-sectional area of the neuroepithelium was 
diminished in Pax3 mutants compared with wild-type embryos (Fig. 4G), as were the dorso-
ventral height and medio-lateral width of the neural tube, but not their relative ratio (Fig. S4G-
J). The significant deficit of cells and size of the Pax3-mutant neural plate, detected in 14-15 
somite stage embryos, was still evident at the 19-20 somite stage (Fig. 4F-G, Fig. S4). These 
findings show that suppression of PNP closure is associated with a proliferation defect in the 
dorsal neuroepithelium. 
 
Overall, Pax3 loss of function in the spinal region causes diminished proliferation without 
induction of neuronal differentiation. It seems likely that Pax3 has comparable functions at 
cranial and spinal levels. Hence, the effect of Pax3 on the balance between proliferation and 
differentiation in the cranial region, where the neuroepithelium is primed to differentiate, may 
be principally mediated through regulation of cell cycle progression rather than direct inhibition 
of differentiation. 
 
In Pax3 mutants, folic acid acts to increase cell proliferation by promoting S-phase to G2 
progression 
Splotch (Pax3Sp2H) was the first mouse model in which NTDs were found to be preventable by 
supplemental folic acid (FA) (Fleming and Copp, 1998), but as in human NTDs the protective 
mechanism has not been defined. FA is reduced via dihydrofolate to tetrahydrofolate (THF), 
which acts to carry one-carbon groups in folate one-carbon metabolism (FOCM), a key function 
of which is to provide one-carbon units for nucleotide biosynthesis. Our previous analysis 
showed no effect of Pax3Sp2H genotype on embryonic folate content at neurulation stages 
(Burren et al., 2008). Here, mass spectrometry-based analysis of the individual folate species 
which comprise FOCM did not reveal significant perturbation in their relative abundance in 
Pax3Sp2H/Sp2H embryos compared with wild-type (Fig. 5A). This is consistent with our finding that 
the relative abundance of s-adenosylhomocysteine and s-adenosylmethionine did not differ 
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with Pax3Sp2H genotype (Burren et al., 2008). Moreover, unlike loss of function mutants of the 
mitochondrial FOCM components: Mthfd1L and Gldc or the mitochondrial folate transporter 
SLC25A32 (Momb et al., 2013; Pai et al., 2015; Leung et al., 2017; Kim et al., 2018), NTDs were 
not prevented by maternal supplementation with formate, a one–carbon donor, in Pax3 
mutants (Table S4). 
 
Cranial neurulation appears highly sensitive to disturbance of cellular proliferation, with 
exencephaly often being induced by teratogens that cause generalised retardation of 
embryonic growth or developmental progression (Copp, 2005). Together with our finding of a 
proliferation defect in the Pax3-deficient cranial and spinal neuroepithelium, this prompted the 
question of whether FA status impacts cell proliferation in developing Pax3Sp2H/Sp2H embryos. 
Indeed, FA is required for proliferation of cultured neural progenitor cells (Ichi et al., 2010; Ichi 
et al., 2011). We therefore carried out further analysis of cell cycle progression in the Pax3 
mutant neural plate in order to determine whether maternal FA treatment could influence cell 
cycle progression. Dams were treated with FA using the protocol that we found to reduce the 
frequency of cranial NTDs among Pax3Sp2H/Sp2H offspring (Burren et al., 2008; Fleming and Copp, 
1998). Embryos were analysed during the period of cranial neurulation at E9.5 (14-15 somite 
stage), with a pulse of BrdU preceding embryo collection to allow analysis of cell cycle 
progression in the midbrain neuroepithelium (Fig. 5B). 
 
The proportion of cells in G2 and M-phase of the cell cycle were analysed on the basis of the 
characteristic appearance of PHH3 imunostaining (de Castro et al., 2012). A lower proportion of 
non-mitotic PHH3-positive (early G2-late G2) cells were present in the dorsal neuroepithelium 
of Pax3Sp2H/Sp2H embryos compared with +/+ littermates (Fig. 5C), corresponding with the 
observed deficit of cells at late G2/M phase (Fig. 3M). In contrast, the mitotic (M-phase) 
population did not differ between genotypes (Fig. 5D). Interestingly, there was a small but 
significantly higher proportion of G2 phase cells in the ventral neuroepithelium of Pax3 mutant 
compared with +/+ embryos, which suggests a possible non-cell autonomous effect of Pax3 loss 
of function. 
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The BrdU labelling index (reporting cells in S-phase) was also significantly diminished in the 
dorsal neuroepithelium of Pax3Sp2H/Sp2H embryos (Fig. 5E), whereas the ventral region did not 
differ from wild-type (Fig. 5E). Hence, both BrdU labelling and PHH3 immunostaining showed 
the presence of a dorsal-high to ventral-low proliferation differential in wild-type embryos that 
is absent, or even reversed, in Pax3 mutants (Fig. 5D-E). 
 
FA treatment had a striking effect on cell cycle parameters, particularly in the dorsal midbrain 
neuroepithelium of Pax3Sp2H/Sp2H embryos where an FA-induced increase in the proportion of 
PHH3-positive, G2-phase cells was observed (Fig. 5C). Similarly, while FA did not significantly 
alter the proportion of S-phase, BrdU-labelled cells there was a trend towards increased 
labelling in all regions (Fig. 5E). Most notably, in FA-treated Pax3Sp2H/Sp2H embryos, we observed 
a significant increase in the proportion of double-positive BrdU/PHH3 cells; i.e. cells that were 
in S phase during the pulse of BrdU labelling and then progressed into G2 by the time of 
embryo collection (Fig. 5F). Hence, the rate of transition from S-phase to G2 was increased by 
supplemental FA. 
 
In the dorsal and ventral neuroepithelium of Pax3+/+ embryos, FA treatment led to non-
significant trends towards increased labelling for both PHH3 (Fig. 5C) and BrdU (Fig. 5E). As a 
result, the dorsal-ventral proliferation differential was absent in FA-treated +/+ embryos. In 
contrast, the proportion of cells in M-phase did not differ with FA treatment in either Pax3 
genotype (Fig. 5D).  
 
Discussion 
The Pax3 mutant (Sp2H) mouse provides a model in which to investigate the cause of NTDs that 
are sensitive to folate deficiency and responsive to prevention by FA. Analysis of apoptosis 
markers, together with lack of NTD prevention by inhibition of apoptosis, are incompatible with 
the idea that increased cell death contributes to failure of neural tube closure. Instead, our 
findings suggest that Pax3 is required for cell cycle progression and suppression of neuronal 
differentiation in the dorsal neuroepithelium until completion of cranial neural tube closure. 
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The close correlation between onset of neuronal differentiation and completion of cranial 
neural tube closure that is observed in wild-type embryos is lost in Pax3 mutants. Consistent 
with these observations, anti-sense down-regulation of Pax3 in cultured neuronal ND7 cells 
resulted in morphological differentiation, without apparent cell death (Reeves et al., 1999). 
Similarly, during melanogenesis, Pax3 induces the melanocyte fate but acts to repress terminal 
differentiation until additional differentiation signals are present (Lang et al., 2005). Moreover, 
during myogenesis Pax3 is required in muscle progenitors but must be down-regulated for 
myoblast differentiation (Goljanek-Whysall et al., 2011). Thus, in different cellular contexts, 
including the neuroepithelium, Pax3 may function to maintain committed progenitor cells in an 
undifferentiated, proliferative state until an appropriate developmental stage. 
 
The relationship between Pax3 mutation, cell cycle regulation and folate status is intriguing. 
Function of FOCM depends on adequate abundance of the tetrahydrofolate (THF) ‘backbone’ 
(from maternal diet and/or microbiota) and supply of one-carbon (1C) units. Supplemental FA 
can enhance supply of THF but does not carry a 1C unit. During neurulation the primary 
requirement for 1C units is met by catabolism of serine and glycine in mitochondrial FOCM 
(Leung et al., 2017; Tibbetts and Appling, 2010). This generates formate that is transferred to 
cytoplasmic FOCM in which the intermediates 5,10-methylene THF and 10-formyl THF act as 
the 1C donors in thymidylate and purine biosynthesis, respectively. Conditions of folate-
deficiency further impose a requirement for serine-dependent generation of 5,10-methylene 
THF by the action of SHMT1 (Beaudin et al., 2011), acting in the cytoplasm and/or nucleus 
(Herbig et al., 2002; MacFarlane et al., 2011). 
 
Pax3 genotype does not affect embryonic folate content at neurulation stages (Burren et al., 
2008) or the relative proportion of different folate intermediates (the current study). This 
contrasts with mouse embryos carrying genetic defects in FOCM-associated enzymes such as 
Mthfr (Leung et al., 2017) and Gldc (Pai et al., 2015) or with methotrexate exposure (a FOCM 
inhibitor)(Leung et al., 2013a). Unlike in Pax3 mutants, NTDs resulting from disruption of the 1C 
supply from mitochondrial FOCM (e.g. by mutation of Gldc or Amt) are neither FA-preventable 
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nor responsive to folate deficiency (Narisawa et al., 2012; Pai et al., 2015). Furthermore, while 
NTDs in Gldc and Mthfd1L null embryos are preventable by maternal supplementation with 
formate as a 1C donor (Leung et al., 2017; Momb et al., 2013; Pai et al., 2015), we found no 
apparent protective effect of this treatment in Pax3 mutants. These findings highlight the 
potential for non-equivalent mechanisms underlying FA-mediated prevention of NTDs 
compared with prevention by 1C donors (e.g. formate) of NTDs resulting from disruption of 
FOCM.  
 
Overall, it appears unlikely that NTDs in Pax3 (splotch) embryos result from a deficit in folate 
uptake, 1C supply or interconversion of folate intermediates in FOCM. Significantly however, 
Pax3 mutant embryos and embryonic fibroblasts preferentially use the nucleotide salvage 
pathway over de novo thymidylate biosynthesis, suggesting a possible impairment of FOCM 
that could underlie sensitivity to maternal folate status (Beaudin et al., 2011; Burren et al., 
2008; Fleming and Copp, 1998). Moreover, the mutual NTD-exacerbating pairwise interactions 
of folate deficiency, Shmt1 loss of function and Pax3 mutation further implicate thymidylate 
synthase as an FA-sensitive process for neural tube closure (Beaudin et al., 2011; Burren et al., 
2008; Martiniova et al., 2015). For example, folate deficiency or Pax3 mutation can cause NTDs 
in Shmt1 null embryos, which do not exhibit NTDs on a folate-replete diet (Beaudin et al., 
2011). While the apparent deficit of de novo thymidylate synthesis in Pax3Sp2H mutants, under 
normal dietary conditions, is not due to a limiting pool of 5,10-methylene THF it may instead 
relate to post-transcriptional down-regulation of thymidylate synthase, as found in Pax3Sp 
mutant embryos (Beaudin et al., 2011). A lowering of THF availability in folate deficient 
conditions could then further suppress thymidylate synthesis and exacerbate NTDs. This would 
also be consistent with the increased frequency of Pax3-related NTDs caused by loss of function 
of Shmt1, whose translocation to the nucleus favours use of 5,10-methylene THF in thymidylate 
synthesis over reduction to 5-methyl THF for methylation of homocysteine (Herbig et al., 2002).  
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We previously found that maternal dietary folate deficiency limits embryonic growth and 
developmental progression of wild-type and Pax3 mutant embryos without dissociating these 
parameters (Burren et al., 2008).  Here, we find that supplemental FA stimulates cell cycle 
progression and that this effect is mediated via an increased rate of transition through S-phase 
and into G2-phase. An effect of FA in the DNA synthesis phase of the cell cycle correlates with a 
proposed mechanism of FA action in stimulating thymidylate biosynthesis.  
 
Notably, the effect of FA in driving cell cycle progression was greatest in Pax3 mutant regions, 
such that the overall effect was to normalize the dorsal-ventral proliferation gradient in 
Pax3Sp2H/Sp2H embryos. It appears that dorsal proliferation per se, as opposed to the dorsal-
ventral gradient specifically, is associated with NTD prevention as FA-treated wild-type embryos 
no longer exhibit a proliferation gradient, but all complete closure. The particular requirement 
for cellular folate in the dorsal neuroepithelium is highlighted by the notable dorsal 
(overlapping the Pax3 expression domain) versus ventral enrichment of mRNA for the folate 
receptor, Folr1, (Saitsu et al., 2003), whose knockout also causes NTDs (Piedrahita et al., 1999). 
Overall, we hypothesise that supplemental FA contributes to neural tube closure by promoting 
S-phase cell cycle progression, particularly in the neuroepithelial component of the dorsal 
neural folds. 
 
Materials and Methods 
Mice and collection of embryos 
PaxSp2H (Sp2H; splotch) mice were maintained as a closed, random-bred (heterozygous with wild-
type) colony. The Sp2H mutation is carried on a mixed background which includes CBA/Ca, 101 
and C3H/He. Experimental litters were generated by intercross of heterozygous mice. Embryos 
were genotyped by PCR of genomic DNA (Conway et al., 1997). To generate mice lacking p53, 
Trp53flox/+ (Jonkers et al., 2001) were used to generate Trp53+/- heterozygotes for intercross to 
Pax3Sp2H. The Pax3cre allele was used as a null allele in crosses with the p53 null allele (Engleka 
et al., 2005).   
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Pifithrin-α (Calbiochem) treatment at a dose of 2.2 mg/kg was achieved by intra-peritoneal 
injection with 0.22 mg/ml solution (diluted with PBS from a 5 mg/ml stock in sterile DMSO), at 
E8.5 and 9.5 (Pani et al., 2002). Folic acid (20 mg/kg) was administered by intra-peritoneal 
injection of dams at E7.5, 8.5 and 9.5, using a dose that we have found to lower frequency of 
NTDs (Burren et al., 2008; Fleming and Copp, 1998). Embryos were collected 3 hours after the 
final injection. Formate treatment was by addition of sodium formate (30 mg/ml) in the 
drinking water of the dam from E0.5 until collection of litters (Pai et al., 2015). Litters were 
dissected from the uterus in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal 
calf serum. Embryos were rinsed in phosphate buffered saline (PBS) and fixed in 4% 
paraformaldehyde. Embryos were dehydrated in a methanol series and stored at -20C prior to 
in situ hybridisation or TUNEL analysis. 
 
For immunohistochemistry, BrdU (Invitrogen) was administered by maternal intraperitoneal 
injection at 50 mg/kg from a stock solution of 10 mg/ml. Litters were collected after 15 
minutes, embryos explanted in ice-cold DMEM, immediately fixed in 4% paraformaldehyde, 
dehydrated through an ethanol series and processed for wax embedding. 
 
Whole embryo culture 
Embryos were explanted at E8.5 leaving the yolk sac and ectoplacental cone intact and cultured 
for 40 hours in rat serum at 38C (Dunlevy et al., 2006; Pryor et al., 2012). Stock solutions of 50 
and 100 mM Z-VAD-FMK (Sigma-Aldrich) in dimethylsulfoxide (DMSO) were added to cultures 
as 0.2% (v/v) additions. An equivalent volume of vehicle was added to control cultures, and 
embryos were randomly allocated to treatment groups. 
 
TUNEL labeling 
TdT-mediated dUTP-biotin nick end labelling (TUNEL) of whole embryos (Dunlevy et al., 2006) 
was performed on a minimum of 8 embryos of each genotype at E8.5, E9.0, E9.5 and E10.5. 
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Whole mount in situ hybridisation (WMISH) 
Whole mount in situ hybridisation (De Castro et al., 2018) was performed using sense and anti-
sense digoxygenin-labelled riboprobes for Pax3 (Conway et al., 1997), generated using a 
digoxygenin RNA labelling kit (Roche) and purified on Chroma spin columns (Clontech).  
 
Immunohistochemistry  
Immunostaining using antibodies for PHH3 (06-570 Merck Millipore) and activated caspase-3 
(Cell Signalling Technology) was performed on paraffin-embedded coronal (cranial) or 
transverse (spinal) sections. Numbers of positive cells were counted in defined areas, blind to 
genotype (Dunlevy et al., 2006).  The number of positive cells per section was normalised to the 
area of neuroepithelium (cells/1000 µm2) or the total number of neuroepithelial cells on the 
section as detected by DAPI staining (% labelling). 
 
Double staining for PHH3 and BrdU was performed following deparaffinising of slides by 
HistoClear. Sections were rehydrated through an ethanol series and antigen retrieval was 
performed in 0.01 M citric acid (pH 6.0). After washing in phosphate buffered saline (PBS), 0.1% 
Triton-X100, slides were blocked in 5% sheep serum, 0.15% glycine, 2% BSA, followed by 
addition of anti-PHH3 (1:300). Secondary antibody was Alexa Fluor 568 (A11077, Life 
Technologies), diluted 1:500 in blocking solution. Nuclear stain was 4’,6-diamidino-2-
phenylindole (DAPI), diluted in PBS (1: 10,000). After post-fixation in 4% PFA, slides were 
incubated in 1 M HCl, followed by 2 M HCl, to expose the BrdU antigen, and neutralised by 
washing in 0.1 M sodium borate (pH 8.5). Slides were blocked in 10% sheep serum and 
incubated with anti-BrdU (347583, BD Bioscience; 1:100). After incubation with secondary 
antibody (Alexa Fluor 488; A11070, Life Technologies; 1:500), slides were mounted (12.5% 
Mowiol 4-88 (Sigma-Aldrich), 0.2 M Tris base, 0.2 M Tris-HCl, 30% glycerol, pH 6.8). Images 
were acquired on an inverted LSM710 confocal microscope (Zeiss).  
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For TuJ1 (β-tubulin type III) staining, 15 µm coronal cryosections were prepared (Burns and 
Douarin, 1998). Sections were blocked (PBS, 10% heat-inactivated sheep serum, 0.1% Triton-X-
100) and treated with primary antibodies against TuJ1 (1:1000 in blocking solution, BAbCO) or 
Pax3 (1:50, ATCC), followed by secondary antibody (goat anti-mouse Alexa-488, 1: 500, 
Southern Biotech). Sections were mounted in Vectashield with DAPI (Vector Laboratories). The 
number of TuJ1-positive cells in 3 adjacent matched sections of forebrain and midbrain was 
counted for each embryo. 
 
For whole mount immunostaining embryos were fixed in methanol/DMSO (4:1) and incubated 
in methanol/DMSO/30% hydrogen peroxide (4:1:1). Embryos were blocked in PBS containing 
2% non-fat dried milk, 0.5% Triton X-100 and 10% sheep serum, and then incubated in the same 
solution with antibody to TuJ1 (1:1000) followed by secondary antibody (Alexa-488 donkey 
anti-mouse; 1:500, Invitrogen). 
 
Analysis of folates by mass spectrometry 
Analysis of multiple folates was performed by UPLC-MS/MS as described previously (Leung et 
al., 2017; Pai et al., 2015). Folates were measured by multiple reaction monitoring (MRM) with 
optimised cone voltage and collision energy for precursor and product ions as described 
(Cabreiro et al., 2013; Leung et al., 2013b) (Leung et al., 2013a). 
  
Statistical analysis was performed using Sigmastat version 3.5 (Systat Software). 
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Figures 
 
 
 
Figure 1. Apoptosis in the neuroepithelium is not affected by Pax3 genotype. (A-F) TUNEL 
staining of embryos at E8.5 (A-B), E9.5 (C-D) and E10.5 (E-F) does not indicate any increase in 
the number of apoptotic cells in the neuroepithelium of Pax3Sp2H/Sp2H mutants (B, D, F), 
compared with wildtype (Pax3+/+; A, C, E) embryos at the stages encompassing neural tube 
closure (A-B, ventral view; A’-B’, dorsal view). The characteristic midline staining in the closed 
mid-forebrain of +/+ embryos (arrowhead in C’, E’) appears to be lacking in Pax3Sp2H/Sp2H 
embryos (D’, F’), although staining at the rostral limit of the forebrain (anterior neural ridge) 
and lateral hindbrain (a site of neural crest cell migration) were present (black arrows in C-D). 
Scale bar represents 0.1 mm. (G) Quantitative analysis of cleaved caspase-3 immunostaining 
in the cranial neuroepithelium reveals no difference between genotypes. (Black circles 
represent single embryos with mean ± SD of this data shown in bars. Data for each embryo 
comprise 2-3 sections; overall 15-37 sections per genotype). See also Figure S1. 
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Figure 2. NTDs in Pax3 mutant embryos are not prevented by apoptosis inhibition. 
Treatment of cultured embryos with Z-VAD-FMK (strategy in A) did not impede cranial neural 
tube closure in +/+ embryos (E) but led to increased frequency of exencephaly among 
Pax3Sp2H/SpH and Pax3Sp2H/+ embryos compared with vehicle (DMSO) controls of the same 
genotype (* P<0.01; Fisher Exact test). TUNEL staining confirmed that apoptosis was 
suppressed in (C) Z-VAD treated embryos, compared to (B) vehicle-treated controls 
(apoptotic cells indicated by arrow in B’). N = 5-12 embryos per genotype for each treatment 
group (See Table S1 for numbers of embryos and measures of developmental progression 
and growth). 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
Figure 3. Premature neuronal differentiation and diminished proliferation in Pax3-mutant 
midbrain neuroepithelium. (A-B) Among Pax3Sp2H/2H embryos exposed to pifithrin- (via 
maternal administration), the frequency of exencephaly (arrowhead in B) was significantly 
lower than among vehicle-treated controls (*p<0.02; Fisher Exact test). Data from 10 treated 
and 37 control litters, see Table S2 for additional details. Pax3 mRNA (C) and protein (D) are 
expressed in the dorsal neural tube (D, above dotted line on coronal section through the 
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midbrain). β-tubulin type III (Tuj1)-positive cells were analysed on coronal sections through 
the forebrain (E-F) and midbrain (G-J) at E9-9.5 (positions of sections in H and K shown on 
inset whole mount image). Scale bar represents 100 µm. (G-I, K) The midbrain 
neuroepithelium of Pax3Sp2H/2H embryos exhibits significantly more neuronal cells than in 
wild-type at the 14-15 somite stages (* indicates significant difference compared with wild-
type embryos at same somite stage, P<0.002). (J-K) Pifithrin-α treatment results in 
significantly reduced number of TuJ1-positive cells in the midbrain of Pax3Sp2H/2H embryos at 
the 15 somite stage (# indicates significant difference compared with both +/+ and untreated 
Sp2H/Sp2H embryos, P<0.002). Each data point represents mean (± SEM) for 9-12 sections 
from a minimum of 3 embryos. (M) The proportion of PHH3-positive (late G2-M phase) cells 
was significantly lower in the dorsal neuroepithelium of the midbrain of Pax3Sp2H/2H embryos 
compared with +/+ littermates at E9.5 (14-15 somite stage; * P<0.01, ANOVA). Black circles (n 
= 5 embryos per genotype) represent single embryos with mean ± SEM of this data shown in 
bars (data for each embryo comprise 5 sections, n = 25 sections per genotype). 
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Figure 4. Diminished proliferation and altered dimensions in the spinal neural tube of 
Pax3Sp2H/2H embryos. (A) PNP length of Pax3Sp2H/2H embryos is enlarged from E9 (10-11 somite 
stage) onwards and delayed PNP closure is also evident in Pax3Sp2H/+ embryos compared with 
stage-matched +/+ controls (*p<0.05, **p<0.01; ANOVA). (B-C) Staining for III-tubulin is detected 
in the spinal neural tube at E9.5 but the caudal limit (indicated by white arrowhead) does not 
approach the open PNP region (white arrow). See also Fig. S3.  (D-G) Analysis of transverse 
sections (D’) at the level of the closing neural folds (boxed in D) at E9.5 (14-15 somite stage) 
shows (E) a significantly lower proportion of PHH3-positive (late G2-M phase) cells in the Pax3-
mutant dorsal neuroepithelium of Pax3Sp2H/2H compared with +/+ embryos (*P<0.01; t-test). The 
neuroepithelium of Pax3Sp2H/2H embryos displays a significantly lower number of cells (F) and 
cross-sectional area (G) than in +/+ embryos at both 14-15 and 19-20 somite stages (*P<0.05; 
**P<0.01). Bars in E-G represents mean ± SEM from 6 embryos per group (genotype and stage) 
with 5-6 sections per embryo (each bar corresponds to 32-36 sections). 
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Figure 5. Folic acid promotes cell cycle progression in the Pax3 mutant neuroepithelium.  
(A) The relative proportion of differing folate species, separated by mass spectrometry, did 
not differ with genotype (DHF, dihydrofolate; THF, tetrahydrofolate; CH=THF, methenyl-THF; 
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CH2, methylene; CH3, methyl; CHO, formyl-THF)(n = 4 embryos per genotype). (B) Scheme 
for in vivo treatment with FA prior to embryo collection with analysis of the midbrain 
neuroepithelium for (C) PHH3 labelled cells in G2 phase, and (D) M-phase, or (E) BrdU 
labelling of S-phase. (F) Proportion of BrdU/PHH3 co-labelled cells in the dorsal 
neuroepithelium. Significant differences between genotypes, or between dorsal and ventral 
regions within treatment groups, are indicated (*P<0.025; **P<0.0025; ANOVA). FA 
treatment led to increased PHH3 (C) and PHH3/BrdU double labelling (F) in the dorsal 
neuroepithelium of Pax3 mutants (##P<0.01; ANOVA). 
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 Genotype No. embryos No. exencephaly (%) No. open PNP (%) 
Pax3 ; Trp53    
Sp2H/Sp2H    ; +/+ 5  4  (80%%) 3/3 (100%) 
Sp2H/Sp2H   ; +/- 24 12 (50%) 15/17 (88.2) 
Sp2H/Sp2H    ; -/- 9 8  (88.9%) 3/3(100%) 
Sp2H/+        ; +/+ 31 0  (0%) 0/25 (0%) 
Sp2H/+        ; +/- 38  1  (2.6%) 0/23 (0%) 
Sp2H/+        ; -/- 26 9  (34.6%)* 2/19 (10.5%) 
+/+             ; +/+ 5 0  (0%) 0/2 (0%) 
+/+             ; +/- 31  1  (3.2%) 1/25 (4%) 
+/+             ; -/-  8 1  (12.5%) 0/4 (0%) 
Table 1. Frequency of neural tube defects among offspring of Pax3Sp2H/+:Trp53+/- intercrosses. 
Litters were analysed at E10.5 for the presence of exencephaly (cranial NTDs) and/or a 
persistently open posterior neuropore (PNP) in embryos with 30 or more somites, which is 
indicative of incipient spina bifida. Cranial and spinal NTDs occurred at high frequency in 
PaxSp2H/Sp2H embryos irrespective of Trp53 genotype, arguing against a protective effect of p53 
loss of function. Cranial NTDs were more frequent among in PaxSp2H/+ heterozygotes that lack 
p53 than in PaxSp2H/+ embryos that were wild-type for p53 (*p<0.05; z-test). Genotype 
frequencies did not depart significantly from Mendelian expectation (p=0.34; chi-square). 
 
 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
Supplementary Material 
Treatment/ 
Genotype 
No. Exen PNP length 
(mm) 
Somites Crown-rump 
length (mm) 
Yolk sac 
circulation 
Control-DMSO 
Sp2H/Sp2H 12 3 (25%) 1.21 0.16* 24.9 0.3 3.29 0.09 2.6 0.1 
Sp2H/+ 15 0 0.46 0.06 25.3 0.3 3.36 0.07 2.4 0.2 
+/+ 8 0 0.36 0.06 25.3 0.5 3.40 0.11 2.6 0.2 
100 M ZVAD 
Sp2H/Sp2H 5 2 (40%) 0.90 0.13* 25.0 0.4 3.25 0.12 2.8 0.2 
Sp2H/+ 7 1 (14%) 0.53 0.09 25.1 0.6 3.25 0.12 2.9 0.1 
+/+ 8 0 0.28 0.04 25.9 0.6 3.27 0.13 2.3 0.3 
200 M ZVAD 
Sp2H/Sp2H 9 8 (89%)# 0.97 0.13* 24.3 0.6 3.11 0.12 2.0 0.3 
Sp2H/+ 12 5 (42%)# 0.55 0.05** 24.4 0.7 3.17 0.12 2.0 0.3 
+/+ 12 0 0.33 0.03 24.5 0.5 3.12 0.10 2.0 0.2 
Table S1. NTD incidence, growth and development of splotch embryos cultured in 
the presence of ZVAD-FMK or DMSO only (vehicle control). Embryos were cultured for 
40 hours from E8.5-10. No significant differences were detected in yolk-sac circulation 
score (ranked from 0: no circulation to 3: vigorous circulation throughout the 
yolk sac), crown-rump length or number of somites after culture, suggesting that there was 
#  no adverse effect on viability, growth or developmental progression, respectively.  
Frequency of exencephaly (Exen) was signifcantly higher among embryos exposed to 200 
M ZVAD than among embryos of the same genotype exposed to DMSO (p < 0.025; Z-test).
* Mean posterior neuropore (PNP) lengths of Sp2H/Sp2H embryos were significantly larger
than for heterozygous and wild-type embryos, reflecting the incipient spina bifida. ** The 
PNP was longer in Sp2H/+ than in +/+ embryos and this was statistically significant in the 200 
µM treatment group. No difference in PNP length was noted between treatment groups. 
Values are presented as mean ± SEM. 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Treatment/Genotype No. 
litters 
No. 
embryos 
No. exencephaly 
(%) 
No. spina bifida 
(%) 
Controls 37 225 
Sp2H/Sp2H 57 35 (61%) 20 (87%) 
Sp2H/+ 106 0 (0%) 0 (0%) 
+/+ 62 1 (2%) 0 (0%) 
Pifithrin-α 10 60 
Sp2H/Sp2H 16 4 (25%)* 14 (88%) 
Sp2H/+ 27 0 (0%) 0 (0%) 
+/+ 17 0 (0%) 0 (0%) 
Table S2. Incidence of neural tube defects among litters of Splotch (Sp2H) mice treated
with pifithrin-α. Dams were treated with pifithrin-α at E8.5 and E9.5, by intra-peritoneal 
injection at a dose of 0.22 mg/kg (10 µl/g of a 2.2 mg/ml stock solution), and controls were 
injected with the same volume of PBS. Litters were collected at E11.5 and analysed for the 
presence of neural tube defects. Mean litter size did not significantly differ between 
treatment groups.* Frequency of exencephaly is significantly lower among Sp2H/Sp2H  
embryos exposed to pifithrin-α than among PBS-treated (p<0.05; Z-test with Yates 
correction), whereas spina bifida frequency is not affected by pifithrin-. 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Developmental 
Stage 
No. 
litters 
Genotype No. 
embryos 
Somite 
number 
Crown-rump 
length (mm) 
E9.5 14 +/+ 22 15.7  0.5 2.2  0.2 
Sp2H/+ 43 15.1  0.2 2.1  0.1 
Sp2H/Sp2H 23 15.9  0.3 2.2  0.1 
E10.5 6 +/+ 11 30.9  0.8 4.3  0.1 
Sp2H/+ 17 30.0  0.5 4.1  0.1 
Sp2H/Sp2H 8 30.3  0.6 4.2  0.1 
Table S3. Number of somites and crown-rump length do not differ between splotch (Sp2H) 
genotypes. Litters were collected at E9.5 and E10.5, the number of somites was counted 
and the crown-rump length measured using an eye-piece graticule. No significant 
differences between genotypes were detected at either stage of development. Values are 
presented as mean ± SEM. 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Genotype/treatment No. 
embryos 
No. exencephaly 
(%) 
No. spina bifida 
(%) 
Formate 33 
Sp2H/Sp2H 5  3  (60.0%) 5 (100%) 
Sp2H/+ 18 0  (0%) 0  (0%) 
+/+ 10 0  (0%) 0  (0%) 
Controls 168 
Sp2H/Sp2H 37 25  (67.6) 35 (94.6%) 
Sp2H/+ 70 0  (0%) 0  (0%) 
+/+ 31 0  (0%) 0  (0%) 
Table S4. Frequency of neural tube defects among offspring of formate-treated mice. 
Litters were generated by intercross of Sp2H/+ mice. Dams were treated with formate (30 
mg/ml in drinking water) and litters were analysed at E11.5 for the presence of 
exencephaly (cranial NTDs) and/or spina bifida. 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Supplementary Figures 
Figure S1. TUNEL staining of wild-type and Pax3Sp2H/Sp2H mutant embryos at E9.0. (A-B) No 
difference in numbers of TUNEL-positive apoptotic cells were detected in the neural folds of 
the cranial region (A, anterior view of forebrain; B, view of hindbrain). (C-D) There was no 
indication of excess TUNEL staining in the spinal region of Pax3Sp2H/Sp2H embryos, whereas 
some mutants exhibited fewer positive cells in the region of open spinal neural folds 
(compare D’ and C’). Scale bar represents 0.1 mm (A-B), 0.25 mm (C-D). 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Figure S2. Pax3 expression in the dorsal neural epithelium and failure PNP closure in 
Pax3Sp2H/Sp2H mutant embryos. (A-C) In situ hybridisation for Pax3 shows expression in the 
dorsal neuroepithlium (arrowheads) in the cranial (B) and spinal (C) regions, as well as 
dermomyotome (arrow). (D-E) Raw data corresponding to Fig. 3A. Measurements of PNP 
length (indicated by blue line in D) show enlargement of PNP length in Pax3Sp2H/2H embryos 
from E9 (10-11 somite stage) onwards. Delayed PNP closure is also evident in Pax3Sp2H/+ 
embryos compared with stage-matched +/+ controls (*p<0.05; **p<0.01; ***p<0.001; 
ANOVA). 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Figure S3. Neuronal differentiation does not occur at the level of PNP closure in wild-type 
or Pax3 mutant embryos (related to Fig. 4). (A-C) Immunostaining for III-tubulin (Tuj1 in 
embryos at E9.5 (17-21 somite stage) confirms presence of positive cells at upper spinal 
levels (A) as seen in whole mount staining (Fig. 4B-C), whereas no positive cells are present 
the level of the recently closed neural tube rostral to the PNP closure site (B, C) in either 
wild-type or Pax3 mutant embryos (images are representative of 3 embryos of each 
genotype; scale bar represents 50 µm). (D) The caudal-most limit at which III-tubulin (Tuj1) 
positive cells were detected was defined on the basis of the level of the somite adjacent to 
the neural tube. Among embryos at late E9.5 (23-24 somite stage), there was no significiant 
difference in the caudal level to which neuronal differentiation had progressed (n = 4 
embryos per genotype).  
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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Figure S4. Analysis of proliferation, cell numbers and spinal neural tube size among wild-
type and Pax3Sp2H/Sp2H mutant embryos at E9-9.5. (A-B) Immunostaining for PHH3 shows a 
significant dorsal-ventral difference in the number of cells at late G2-M phase in wild-type 
embryos (*P<0.05) but not in Pax3 mutants (data re-plotted from Fig. 3). Dorsal and ventral 
regions used for analysis (A) correspond to Pax3-positive and negative regions, respectively. 
(C-E) The number of cells in transverse sections through the spinal neuroepithelium was 
lower in Pax3Sp2H mutants than in +/+ embryos in both the dorsal and ventral regions 
(labelled D and V in panel C) at the 14-15 and 19-20 somite stages. (F) Overall cell density 
(cells/mm2) did not differ between genotypes. (G-J) The dorsal-ventral height (H) and lateral 
width (W) of the spinal neuroepithelium was diminished in Pax3Sp2H mutant embryos, but 
the height/width ratio did not differ from wild-type. (*P<0.05; **P<0.01; ANOVA); scale bars 
represent 50 µm. Bars represent mean ± SEM from 6 embryos per group (genotype and 
stage) with 5-6 sections per embryo (each bar corresponds to 32-36 sections). 
Disease Models & Mechanisms: doi:10.1242/dmm.042234: Supplementary information
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